Navigation Links
Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
Date:6/9/2008

SAN FRANCISCO, June 9 /PRNewswire/ -- Two long-term, large-scale and independent studies evaluating cardiovascular (CV) outcomes in people with type 2 diabetes enrolled more than 9,300 patients taking AVANDIA(R) (rosiglitazone maleate) and provide more than 20,000 patient years of additional experience with AVANDIA. The Veterans Affairs Diabetes Trial (VADT), through two separate analyses, concluded that based on results from VADT, there is no evidence to suggest that use of AVANDIA increases the risk for CV mortality and morbidity in patients with type 2 diabetes. A second trial, The Action to Control Cardiovascular Risk in Diabetes (ACCORD), found that AVANDIA was not associated with any increased risk of death. These findings display a safety profile consistent with results from other long-term studies with AVANDIA. These studies were presented during the 68th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA.

"The findings on AVANDIA should be reassuring to physicians who prescribe AVANDIA and patients who use AVANDIA for their type 2 diabetes," added R. Paul Aftring, MD, PhD, AVANDIA Clinical Lead at GlaxoSmithKline. "The safety findings on AVANDIA from these two trials add substantial patient experience to the large body of existing evidence on the safety profile of the medication."

Findings from VADT

VADT evaluated whether intense blood sugar control in patients with type 2 diabetes would reduce major CV events. The study continued for 7.5 years. In total, 1,704 patients enrolled in VADT took AVANDIA.

The primary result of VADT did not show that intensive blood sugar control (HbA1c levels below 7%) had a statistically significant effect on reducing major CV events associated with diabetes. However, there was a favorable trend in reducing all CV events, except CV death and inoperable heart disease, among the patients in the intensive arm. There were significantly fewer CV events in the trial
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
5. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... 21, 2013  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ... acute and breakthrough pain, today announced top-line ... 3 study of its investigational sublingual Sufentanil ... the primary efficacy endpoint was achieved.  The ...
Breaking Medicine Technology:U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
(Date:5/21/2013)... 2013 Swimsuit season is almost here. The ... products has begun with a 35% discount. , Cellulite forms ... women get the dreaded cellulite even if they are in ... where they have been stored as toxic lymph and smashed ... fixes, a specific program that works to dissolve the toxins ...
(Date:5/21/2013)... Feed additives have now become an essential ... Most of the feed additives are used in micro ... powders. There are variety of feed additives available that ... the type of animal and feed. Nutritional feed additives ... nutrition to the animal in order to gain lean ...
(Date:5/21/2013)... (May 22, 2013)Today the George Washington (GW) ... Services (SPHHS) announced the launch of the ... Health, a collaboration between SPHHS, the Maryland ... other community partners. This university-community partnership aims ... affect Latino communities through research, mutual capacity ...
(Date:5/21/2013)... Medical Ministry International announced today that ... by GreatNonprofits , the leading provider of user reviews ... a Top-Rated 2013 Nonprofit,” says Samuel Smith, MMI CEO. ... 3000 Volunteers and Staff serving in 22 countries around the ... those that have seen our work first hand and wanted ...
(Date:5/21/2013)... Diego, CA (PRWEB) May 21, 2013 ... adding materials showing how to use 17 DISC applications ... is a natural progression. , The July 25 ... feature the top 17 ways of applying DISC. The ... DISC certified graduates. The user-friendly DISC training ...
Breaking Medicine News(10 mins):Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4
... ... ... known for its ability to heal, but it can often be a costly expense that ... leaders in health care career training, for the care they need. , , , , ...
... , , BOCA RATON, Fla., Sept. ... cleaning franchise company, announced today that it has been named a ... the most coveted awards programs in the business community. , ... following American Business Awards categories: "Best Overall Company of the Year," ...
... PLYMOUTH MEETING, Pa., Sept. 3 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... participate in the following conferences: , , -- Robert ... September 9-10, 2009 at the Four Seasons ... will present at 2:15 pm ET on September 9, 2009 and meet, ...
... , , , QUITO, Ecuador, ... and epilepsy that make her life on the steep mountainside above ... is priceless! , , (Photo: ... the Multimedia News Release, go to: http://www.prnewswire.com/mnr/childreninternational/38836/ ...
... ALBANY, Ore., Sept. 3 At just 31 years of ... set out to take on the giants in the head lice industry. ... potentially toxic head lice treatment that "smelled like bug spray" on her ... liquid would seep into her daughter,s eyes. , , ...
... Vt., Sept. 3 Dominion Diagnostics (Dominion) will host an ... 7 p.m. at its new Williston, Vermont laboratory. ... medical laboratory that provides comprehensive clinical quantitative urine drug testing, ... 2009, Dominion opened its new Vermont laboratory in order to ...
Cached Medicine News:Health News:Free Massage Therapy Sessions Offered at CDI College 2Health News:Coverall Honored as Finalist in Six Categories for 2009 Stevie Awards 2Health News:Coverall Honored as Finalist in Six Categories for 2009 Stevie Awards 3Health News:BMP Sunstone Announces September Investor Conference Participation 2Health News:Photo: Poor Disabled Children in Ecuador Receive Free Wheelchairs! 2Health News:Photo: Poor Disabled Children in Ecuador Receive Free Wheelchairs! 3Health News:Single Mom's Clever Idea: Kill Head Lice With Salt 2Health News:Single Mom's Clever Idea: Kill Head Lice With Salt 3Health News:Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility 2
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... The Holding Clamps have a slender design ... sequential tensioning of Kirschner wires. The Connecting ... Fiber Rods and/or Connecting Bar. Uses 3.0 ... tip Kirschner wires eliminate need to predrill ...
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
Medicine Products: